FOLR1 and neoplasm: MOv18-SB-Saporin, targeting the tumour-associated antigen Folate Receptor α (FRα) caused a concentration-dependent decrease in viability of FRα-high CAL51, but not of FRα-low MDA-MB-468 breast cancer cells (Fig. 1f).